Evidence map›Paper›PMID 41627979›Full record

Observational studyCancer science2026

Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With Atezolizumab.

Atsuto Mouri, Hiroshi Kagamu, Koji Tamada, Makoto Nishio, Hiroaki Akamatsu, Yasushi Goto, Hidetoshi Hayashi, Satoru Miura, Akihiko Gemma, Ichiro Yoshino and 15 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Atsuto MouriDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Hiroshi KagamuDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Koji TamadaDepartment of Immunology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.ORCID https://orcid.org/0000-0002-3098-2565
Makoto NishioDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID https://orcid.org/0000-0003-4969-4165
Hiroaki AkamatsuInternal Medicine III, Wakayama Medical University, Wakayama, Japan.ORCID https://orcid.org/0000-0001-5856-5512
Yasushi GotoDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0002-7437-5054
Hidetoshi HayashiDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan.ORCID https://orcid.org/0000-0001-8787-5587
Satoru MiuraDepartment of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.ORCID https://orcid.org/0000-0001-7868-6661
Akihiko GemmaDepartment of Pulmonary Medicine and Oncology, Nippon Medical School, Graduate School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0003-0762-2737
Ichiro YoshinoDepartment of General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
Toshihiro MisumiDepartment of Biostatistics, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan.
Ryota SaitoDepartment of Respiratory Medicine, Tohoku University Hospital, Sendai, Japan.
Noriko YanagitaniDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Fujita MasakiDepartment of Respiratory Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Hiroshi NokiharaDepartment of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Kazumi NishinoDepartment of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Masahiro SeikeDepartment of Pulmonary Medicine and Oncology, Nippon Medical School, Graduate School of Medicine, Tokyo, Japan.
Tetsunari HaseDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID https://orcid.org/0000-0002-9653-8424
Osamu HatajiRespiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie, Japan.
Hiroaki TakeokaDepartment of Respiratory Medicine, NHO Kyushu Medical Center, Fukuoka, Japan.
Yosuke KawashimaDepartment of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Miyagi, Japan.
Hirotaka KurokiChugai Pharmaceutical Co., Ltd., Tokyo, Japan.
Masamichi SugimotoChugai Pharmaceutical Co., Ltd., Tokyo, Japan.
Hiroshi KurikiChugai Pharmaceutical Co., Ltd., Tokyo, Japan.
Tetsuya MitsudomiKindai Hospital Global Research Alliance Center and Thoracic Surgery, Kindai University, Osaka, Japan.ORCID https://orcid.org/0000-0001-9860-8505

Funding

Chugai Pharmaceutical
6 · The paper itself

Abstract

We investigated immunologic biomarkers that predict outcomes of patients with previously treated metastatic non-small cell lung cancer who were enrolled in the J-TAIL study, a prospective, observational study of atezolizumab monotherapy. Of 262 patients participating in the J-TAIL exploratory study, peripheral blood mononuclear cells were obtained from 51 patients and analyzed by T-cell fractionation analysis using Helios mass cytometry and serum proteomics analysis. Following treatment with atezolizumab, an increase in programmed cell death-1 (PD-1)-expressing CD8 and CD4 T-cell populations was observed. A more pronounced increase in PD-1 expression was seen in T cells from patients whose progression-free survival (PFS) was 100 days or longer compared with those with shorter PFS. The proximity extension assay, which is highly sensitive multiplex analysis technology that combines antibody-based affinity assays with next-generation sequencing, showed a significant increase in FOXO1, possibly in response to precursor-exhausted T-cell population activation. Immune-related adverse events were associated with a high percentage of PD-1-positive cells on effector memory CD8 T cells, which was thought to be accompanied by extremely high CD8 T-cell activation. Further analysis distinguished poor prognosis populations with significant differences in CD62L

Indexed as

Antibodies, Monoclonal, HumanizedCarcinoma, Non-Small-Cell LungLung NeoplasmsAgedAntineoplastic AgentsBiomarkers, TumorCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleHumansMaleMiddle AgedProgrammed Cell Death 1 ReceptorProgression-Free SurvivalProspective StudiesProteomicsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsatezolizumabBiomarkers, TumorPDCD1 protein, humanProgrammed Cell Death 1 Receptorimmunotherapynon‐small‐cell lung carcinomaprospective studiesT‐lymphocytestumor biomarkers

Identifiers

PMID41627979
PMCPMC13045310

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.